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Abstract
Background:  Traditional intraperitoneal (IP) therapy administered simultaneously with
intravenous (IV) chemotherapy in the primary setting has been well documented. This
retrospective study was conducted to investigate the role of weekly IP therapy as an inducing
intervention before front-line IV chemotherapy, particularly in patients with bulky residual disease
after surgery.
Methods: A total of 426 patients with advanced ovarian cancer treated between 1990 and 1999,
were reviewed. Follow-up data were available in 409 patients. Of whom, 230 patients received
postoperative weekly IP therapy with a median cycles of 4, other 179 patients who did not receive
any IP therapy were used as the control group.
Results: The median age of the patients was 51 years (range, 20–77 years). One hundred eighty-
nine patients with stage III disease and 41 patients with stage IV disease were treated with
postoperative IP therapy, respectively. Complications and toxicity were observed in 68 patients
(29.5%), but there were no grade 4 toxicities and no patients died of complications or toxicities. In
patients with residual disease > 1 cm, the median survival of those with IP delivery of chemotherapy
and those without was 21.6 months and 18.8 months, respectively (hazard ratio [HR]= 0.69, P =
0.02). Whereas, in patients with residual disease ≤ 1 cm, the median survival was 46.8 months and
37.6 months, respectively (HR= 0.73, P = 0.09). Multivariate analysis suggested that the factors age
≤ 60 years, stage III, IP therapy and paclitaxel as front-line chemotherapy were associated with a
better prognosis for patients with advanced ovarian cancer.
Conclusion: Weekly postoperative IP therapy as an inducing intervention is practical for both
physicians and patients with acceptable complications and associated with a lengthened survival of
patients with advanced ovarian cancer. Whether this arm can be used in lieu of a traditional one
needs further randomized trial to confirm the preliminary results.
Background
Intraperitoneal (IP) therapy is the direct instillation of
chemotherapy into the peritoneal cavity. First proposed
by Dedrick et al, [1,2] IP arm is designed to maximize drug
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delivery to the tumor while avoiding many of the systemic
toxicities associated with intravenous (IV) administration
of the drug. It has been hypothesized previously that the
high local concentration of cisplatin achievable within the
peritoneal cavity after regional administration (10- to 20-
fold greater than measured within the systemic compart-
ment) would exert its maximum benefit in patients with
microscopic residual disease or very small-volume macro-
scopic cancer at the time of IP drug delivery [3]. Support
for this concept comes from early preclinical data where
the depth of penetration of cytotoxic agents directly into
the tumor or normal tissue after regional delivery has
been measured in millimeter or less from the surface of
the peritoneal lining [2,4-6]. A number of phase II trials of
IP therapy have examined in the salvage setting in women
with ovarian cancer have revealed that responses are
almost exclusively observed in individuals with micro-
scopic disease only or in those individuals whose maxi-
mal tumor diameter measures less than 0.5 to 1 cm [7,8].
Mature results are also available from two randomized
phase III trials conducted by the Gynecologic Oncology
Group (GOG) (GOG104, GOG 114) [9,10]. A landmark
study, initiated in the mid 1980s and published in 1996,
compared a regimen of IV cyclophosphamide plus IV cis-
platin to a regimen of IV cyclophosphamide plus IP cispl-
atin [9]. In this trial, the median survival time of patients
treated with IP cisplatin was improved from 41 to 49
months (P = 0.02) and the death HR was reduced by 24%,
in favor of the regional treatment program. Although the
authors claimed less toxicity observed in IP drugs delivery,
25% patients received IP therapy less than 4 cycles. In
addition, a criticism of this trial is that 73% patients with
residual disease ≤ 0.5 cm did not statistically benefit from
IP therapy, in other words, just a cohort of 27% women
with residual disease between 0.5–2 cm benefited most
from this regional treatment program. In the second study
(GOG 114), Markman et al [10], compared the new stand-
ard regimen of IV cisplatin plus IV paclitaxel to a regimen
of moderately high-dose carboplatin followed by IP cispl-
atin plus IV paclitaxel. They documented the median sur-
vival time for women treated with IP therapy was
improved from 52 to 63 months, and the death HR was
reduced by 19%. One may argue a marginally significant
survival improvement (P = 0.05) amounted to a remarka-
ble 11-month prolongation. The results from that trial
were challenged on the basis of the unknown impact of 2
cycles of carboplatin that was used before initiation of the
IP therapy, concern about 18% of women received cycles
of IP therapy. An editorial by McGuire [11] proclaimed
that, in the second trial, savage therapies that might influ-
ence survival end points were not controlled, and how fre-
quently salvage therapies administered before disease
progression that might also influence progression-free
survival was not divulged by the authors.
These results, however, do not lead to the widespread
practice of IP therapy. Why? Controversies remain both
over safety and efficacy of this approach. Consequently,
there is likely considerable room for improvement with
respect to study design. Traditional IP therapy was deliv-
Table 2: Complications and toxicities associated with IP 
therapy*
Complications and toxicity no. %
Catheter related
Catheter malfunction 21 9.1
Catheter-induced infection 5 2.2
Toxicities (Grade 3)
Neuropathy 1 0.4
WBC 7 3.0
Platelets 2 0.9
Other hematologic 13 5.7
Creatine clearance 1 0.4
Gastrointestinal 10 4.3
Others
Chemical peritonitis 2 0.9
Severe abdominal pain 6 2.6
Total 68 29.5
Abbreviation: IP, intraperitoneal; WBC: white blood cell.
* IP used as neoadjuvant therapy is not included.
Table 1: Baseline Patient Characteristics
Characteristics IP therapy Without IP therapy
(n = 230) (n = 179)
Age
<41 33 27
41–60 172 138
>60 14 25
FIGO stage
IIIa 19 8
IIIb 22 6
IIIc 148 128
IV 41 37
Residual disease
≤ 1 cm 123 68
> 1 cm 107 111
Grade
18 4
2 100 67
31 2 2 1 0 7
Not available 0 1
Histology
Serous 116 88
Mucinous 13 18
Endometrioid 25 16
Unspecified adenocarcinoma 44 37
Mixed 7 7
Clear cell 18 7
Others 7 6
Abbreviation: IP, intraperitoneal; FIGO, International Federation of 
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ered simultaneously with IV chemotherapy and repeated
every three weeks. With much different to that in the liter-
ature, this series was carried out to evaluate the role of
weekly IP therapy delivered independently with IV chem-
otherapy.
Patients and methods
We retrospectively reviewed the records of 426 patients
who underwent primary surgery for advanced epithelial
ovarian cancer between 1990 and 1999 at Fudan Univer-
sity Cancer Hospital. Patients received postoperative IP
therapy were compared with those without any IP ther-
apy. IP therapy repeated every week was followed by sys-
temic IV chemotherapy. Follow-up data were available for
409 patients who formed the basis of this study.
Regular IP therapy used independently with IV chemo-
therapy began from 2–7 days after surgery. Two hundred
thirty patients (56.2%) received 2–9 courses (median, 4
courses) of postoperative IP therapy. One hundred and
five women (25.7%) received 1–3 courses (mean, 3
courses) of neoadjuvant IP therapy, which was delivered
before primary surgery and not considered as an inducing
intervention. IP therapies delivered after systemic front-
line intravenous chemotherapy such as those for consoli-
dation or salvage intent were not included in this study. IP
arm consisted of platinum-based combination therapy
administered through a Tenckhoff, or a Port A, or Gros-
hong catheter. Cisplatin, 60 mg/m2, and 5-FU, 800–1000
mg/m2, and/or mitomycin C 6 mg/m2, or etoposide, 100
mg/m2, were given in 1.5–2 liters of normal saline and
administered IP as fast as possible, usually within 2 hrs.
Hydration was given with 1000–1500 ml 5% glucose in 4
hrs.
The cut-off of residual disease in the greatest dimension
after primary surgery was 1 cm. Statistical analysis
included tests for associations between potential prognos-
tic factors and between prognostic factors and survival.
Survival probabilities were estimated by Kaplan-Meier
methods, and prognostic factors for survival were evalu-
ated by a log-rank test (univariate) or a Cox proportional
hazard model (multivariate).
Results
Patient characteristics
The median age of the patients was 51 years (range, 20–77
years). The baseline patient characteristics of the patients
are listed in Table 1. Of the 409 eligible patients, 331 and
78 patients had International Federation of Gynecology
and Obstetrics (FIGO) stage III and stage IV disease,
respectively. Distribution of perioperative IP therapy by
stages was as follows, neoadjuvant IP therapy: stage III,
71; IV, 34; and postoperative IP therapy: stage III, 189; IV,
41. One hundred ninety-one women had residual disease
of ≤ 1 cm after primary surgery, and 218 patients had
residual disease > 1 cm.
Complications and toxicity
Table 2 outlines the major complications and toxicities
encountered by IP chemotherapy after surgery. Complica-
tions and toxicity were observed in 68 patients (29.5%).
There were no grade 4 toxicities and no patients died of
complications or toxicities.
Overall survival by IP therapy and residual disease after pri- mary surgery Figure 2
Overall survival by IP therapy and residual disease after pri-
mary surgery. IP therapy vs. without IP therapy in patients 
with residual disease > 1 cm (HR = 0.69, P = 0.02) (A) and 
residual disease ≤ 1 cm (HR = 0.73, P = 0.09) (B), respec-
tively
Overall survival by IP therapy Figure 1
Overall survival by IP therapy. Black lines: stage III ovarian 
cancer, IP therapy (the solid line) vs. without IP therapy (the 
dash line), χ2 = 9.41, P < 0.01; Gray lines: stage IV ovarian 
cancer, IP therapy (the solid line) vs. without IP therapy (the 
dash line), P > 0.05World Journal of Surgical Oncology 2006, 4:4 http://www.wjso.com/content/4/1/4
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Survival
The median follow-up was 37 months (range, 3–169
months). Neoadjuvant IP therapy was not associated with
the prolongation of survival in patients with advanced
ovarian cancer (P > 0.05). When stratified by FIGO stage,
patients with stage III disease treated with postoperative
IP therapy (χ2 = 9.41, P < 0.01) rather than those with
stage IV disease (P > 0.05) benefited from postoperative IP
therapy (Figure 1). When patients stratified by the size of
residual disease, in suboptimal group (residual disease >1
cm), the median survival of those with IP arm vs. those
without was 21.6 months vs.18.8 months, respectively
(hazard ratio [HR] = 0.69, P = 0.02). (Figure 2A). In opti-
mal group (residual disease ≤ 1 cm), no statistical differ-
ences were seen with respect to survival if patients were
sub-grouped in terms of IP therapy or not (median 46.8
months versus 37.6 months, respectively; HR = 0.73, P =
0.09). (Figure 2B).
Table 3 summarizes the results of multivariate analysis,
which suggested that, when it was stratified by residual
disease (residual disease ≤ 1 cm and >1 cm), the factors
age ≤ 60 years, stage III, IP therapy, and paclitaxel as front-
line chemotherapy were associated with a better prognosis
for patients with advanced ovarian cancer. However, neo-
adjuvant IP therapy was not an independent survival
determinant.
Discussion
The rationale of independent weekly IP chemotherapy
In the past two decades, we used IP therapy between pri-
mary surgery and front-line IV chemotherapy, which was
repeated every week with a median 4 cycles in total. Such
an approach held significant promise in both patients and
the physicians in our hospital. One may argue the ration-
ale of independent weekly IP intervention. It was based on
the observations that the probability of intestinal adhe-
sion increased with the time going after primary surgery
and IP therapy itself might cause the adhesion. During
secondary surgery we also observed that adhesion
occurred more frequently in patients with IP therapy than
those with IV therapy alone. Profound pharmacokinetic
results have documented that higher intracellular drug
levels result from direct tumor penetration and uptake.
Once the adhesion occurring, it is difficulty for active
drugs to pass the surrounded tissues into tumor nodes.
Abdominal pain was common seen in patients with adhe-
sion. That was one of the reasons why some patients were
unwilling to receive IP therapy. We feel that weekly IP
therapy is more practical than the traditional one, which
is used simultaneously with intravenous chemotherapy.
So we usually use this arm within 4 weeks after primary
surgery. To our knowledge, it is the first report to advocate
IP therapy used weekly, independently with IV therapy as
a chemotherapeutic inducing intervention for advanced
ovarian cancer.
Survival impacts of weekly IP chemotherapy
To our surprise, survival benefit from weekly IP therapy is
observed particularly in patients with suboptimal surgical
cytoreduction, and this review documents an 2.8 months
improvement in survival (P = 0.02) and a 31% reduction
in the risk of death in patients treated with induction IP
arm compared to those with upfront IV arm. In patients
with optimal surgical cytoreduction an 9.2 months
improvement in survival is observed, but it does not reach
a statistical significantly difference (HR = 0.73, P = 0.09).
It is different from that reported in the literature, but the
results are quite exciting. The possible explanations for
that might be as follows: (1) weekly IP delivery of chemo-
therapy for about 3 cycles plays different roles of chemo-
therapeutic induction and enhance the efficiency of the
following IV chemotherapy in patients with suboptimal
and optimal surgical cytoreduction. In patients with opti-
mal cytoreduction, IP chemotherapy can eradicate the
small lesions, particularly those of <0.5 cm. The question
is how IP arm works in patients with bulky residual dis-
ease. Till now, in western countries, most oncologists just
advocate IP chemotherapy used in micro-residual disease.
Whereas, widespread microscopic residual disease remain
a problem as well as the bulky lesions when suboptimal
cytoreduction happens. It is indefinite whether or not IP
arm has an effect on bulky nodes, but drugs in peritoneal
can eradicate microscopic disease for those suboptimal
surgical results. At this point, weekly IP chemotherapy
plays an inducing role when it is followed by IV chemo-
therapy. (2) Figure 2A shows some patients with subopti-
mal cytoreduction treated with IP arm survived more than
14 years, whereas in optimal cytoreduction group no
Table 3: Multivariant analysis of effects on overall survival stratified by residual disease after primary surgery.
Variable Harzard 95%CI P value
Age >60 1.26 1.02–1.57 0.03
FIGO stage IV 4.84 2.73–8.57 <0.01
Initial paclitaxel* 0.80 0.71–0.90 <0.01
IP chemotherapy 0.71 0.56–0.90 <0.01
Abbreviation: IP, intraperitoneal; 95%CI, 95% confidential interval; FIGO, International Federation of Gynecology and Obstetrics.
* Paclitaxel as front-line chemotherapy.World Journal of Surgical Oncology 2006, 4:4 http://www.wjso.com/content/4/1/4
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patients treated with IP chemotherapy survived more than
12 years, and that is why the two curves in the former are
significantly separated. Although this series is a retrospec-
tive observation, noteworthy is the significant long-term
survival benefit from IP delivery of chemotherapy. The
curves of both Figure 2A and 2B tend to separate more sig-
nificantly in those after 2 years follow-up than those
within 2 years. In addition, when categorized by the factor
residual disease, multivariate analysis suggests that IP
therapy remains one of the survival determinants. It may
be translated that 4 cycles IP therapy delivered within 5
weeks after surgery is mainly associated with long-term
survival in patients with advanced ovarian cancer. Our
previous studies have documented that 6 cycles IV chem-
otherapy delivered in 18 weeks just improve the 3-year
survival [12,13]. Consequently, we are quite encouraged
by the present results because how to improve long-term
survival remains the major problem in the treatment of
patients with advanced ovarian cancer. Heated/ hyper-
thermia intraperitoneal chemotherapy (HIPEC), which
was first established by Spratt et al, in the late 1970s, had
recently been documented to have a survival advantage
and improvement of quality of life for patients with pseu-
domyxoma peritonei, colorectal-, gastric and ovarian can-
cer [14-16]. However, HIPEC will not used as a regular
arm for patients with ovarian cancer because of its incon-
venient.
Conclusion
The present results suggest that weekly IP delivery of
chemotherapy for 4 cycles should be a standard care for
ovarian cancer. Well-designed randomized controlled tri-
als should be conducted to confirm the results.
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